Imricor Medical Systems (ASX:IMR) said the Lausanne University Hospital in Switzerland performed its first procedure using the company's iCMR cardiac ablation device, according to a Wednesday filing with the Australian bourse.
The move makes the hospital the third site for the company's Visabl-AFL clinical trial being conducted to support the US Food and Drug Administration approval of the company's products, the filing said. It follows the activation of the Johns Hopkins Hospital in the US and the Cardiovascular Institute of South Paris in France.
The company's shares rose past 11% in recent Wednesday trade and earlier hit their highest since November 2021.
Price (AUD): $0.98, Change: $+0.10, Percent Change: +11.36%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.